Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease

Korábbi kezelés

• Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine).
• Active treatment with one or more anti-epileptic agent.
• Active treatment with one or more psychiatric agent (e.g. antidepressants, antipsychotics, etc).

Más betegség

• Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.
• Subjects with history of seizure or epilepsy within the past 24 months.
• Subjects who have had a stroke within the past 24 months.
• Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and/or sacral nerve stimulator.
• Subjects who have profound hearing or visual impairment.

Egyéb

• Subjects who do not have healthcare.
• Subjects with clinically significant suicide risk and/or suicide attempt in the past 12 months.
• Subjects with behavioral problems such as aggression/agitation/impulsivity that might interfere with their ability to comply with protocol.
• Subjects diagnosed with migraine headache.
• Subjects who have a life expectancy of less than 24 months.
• Subjects who are pregnant.

• Subject is between the ages of 50 - 100.
• Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19 -26.
• Subject is willing to sign informed consent document.
• If subject is deemed to not have capacity to sign the informed consent, he/she will need a legally authorized representative to provide surrogate consent.
• Subjects whose primary residence is within 2 hours of Boston
• Able to complete the 1st month of at home stimulation at their primary residence; if subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team.